CME Presentations

Immunotherapy Best Practices: Overcoming Clinical Challenges and Enhancing Treatment in Solid Tumors


Presentations


Speakers

  • Ignacio Wistuba, MD

    Ignacio Wistuba, MD

    Ignacio Wistuba, MD

    Professor and Chair, Department of Translational Molecular Pathology

    Ignacio I. Wistuba, MD, is division head ad interim of the Division of Pathology and Laboratory Medicine, and professor and chair of the Department of Translational Molecular Pathology at M.D. Anderson Cancer Center in Houston, Texas. His research involves the elucidation of molecular abnormalities in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for therapies of solid tumors, which has resulted in over 600 peer-reviewed papers. Dr Wistuba currently serves as the pathologist of the Lung Cancer Mutation Consortium (LCMC), a member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC), and senior editor of Cancer Prevention Research (AACR) and Annals of Oncology (ESMO).
  • Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Roy Herbst, MD, PhD

    Ensign Professor of Medicine (Oncology)

    Roy S. Herbst, MD, PhD, is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut. Dr Herbst has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC). His laboratory work, which focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways, has been translated from preclinical to clinical settings in multiple Phase II and III studies. He has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters.
  • Michelle Rohlfs, MSN, APRN, FNP-BC, AOCNP

    Michelle Rohlfs, MSN, APRN, FNP-BC, AOCNP

    Michelle Rohlfs, MSN, APRN, FNP-BC, AOCNP

    Advanced Practice Registered Nurse

    Michelle Rohlfs, APRN, FNP-BC, AOCNP, is the APP supervisor for the Department of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston. She cares for melanoma patients in the clinic and inpatient units. Michelle began as a nurse working on the inpatient floor in the Melanoma and Sarcoma unit at the MD Anderson Cancer Center. She obtained her Master of Science in Nursing at Texas Woman’s University and became a family nurse practitioner. In 2004, Michelle became a nurse practitioner in the Department of Melanoma Medical Oncology. She has seen many changes in melanoma treatments over the past 23 years. Michelle has treated hundreds of patients with immunotherapy and treats a large population of patients admitted with immune-mediated toxicities.
  • Michael J. Overman, MD

    Michael J. Overman, MD

    Michael J. Overman, MD

    Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine

    Michael J. Overman, MD, is a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston. Dr Overman is focused on improving the outcomes for patients with pancreatic and intestinal cancers, with a strong interest in clinical trials and translational research. He is a principal investigator on numerous studies investigating immune-checkpoint therapy in gastrointestinal malignancies, and has been involved in various clinical trial studies involving small bowel adenocarcinomas. He has published articles in peer-reviewed journals that include the Journal of Clinical Oncology and Annals of Oncology. Dr Overman earned his MD from Johns Hopkins School of Medicine in Baltimore, Maryland.
  • Alan Nguyen, LCSW, OSW-C

    Alan Nguyen, LCSW, OSW-C

    Alan Nguyen, LCSW, OSW-C

    Social Work Counselor

    Alan Nguyen, LCSW, is a licensed clinical social worker in the Melanoma and Skin Center at The University of Texas MD Anderson Cancer Center in Houston. He received his Master of Social Work degree from Baylor University in Waco, Texas and is certified as an oncology social worker. In his 5 years with the Melanoma and Skin Center, his role as a social work counselor has included providing support to patients and their support systems as part of an interdisciplinary team by providing supportive counseling, psychosocial education, connecting patients to community resources, addressing home safety concerns, and helping patients engage in advance care planning discussions.
  • Brian Rini, MD Chief of Clinical Trials, Ingram Professor of Medicine

    Brian Rini, MD Chief of Clinical Trials, Ingram Professor of Medicine

    Brian Rini, MD Chief of Clinical Trials, Ingram Professor of Medicine

    Brian I. Rini, MD, FASCO, is professor of medicine and chief of clinical trials for the Vanderbilt Ingram Cancer Center (VICC) at Vanderbilt University in Nashville, Tennessee. His primary research has been in renal cell carcinoma, with special focus on antiangiogenic therapy and immunotherapy. Dr Rini’s research has been published in peer-reviewed journals, including the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, and Lancet. Certified in Medical Oncology by the American Board of Internal Medicine, he is active in numerous professional organizations, such as ASCO and the Society for Immunotherapy of Cancer (SITC). Dr Rini earned his medical degree at the Ohio State University College of Medicine in Columbus.

CME Information

Immunotherapy Best Practices: Overcoming Clinical Challenges and Enhancing Treatment in Solid Tumors


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

Refining Patient Selection for Biomarker-Directed Immunotherapy
  • Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
  • Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively
Optimizing Management of Adverse Events Associated with Immunotherapy
  • Anticipate unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors
  • Implement expert-recommended best practices for managing adverse effects that can occur with immunotherapy
Life After Immunotherapy: Coordinating Care and Survivorship Plans
  • Apply recent guidelines and expert recommendations for the creation of comprehensive survivorship plans for patients who have received immune checkpoint inhibitors
  • Plan strategies on developing survivorship plans within your multidisciplinary cancer care team
Evidence-Based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations
  • Examine the relevance of phase II and III trial data regarding emerging indications in solid tumors for immune checkpoint inhibitors
  • Assess latest clinical trial data on immune checkpoint inhibitors across a wide range of tumors and implement new practice standards accordingly
  • Recognize the rationale(s) behind combining checkpoint inhibitors with other anti-cancer drugs, including chemotherapy, targeted therapies, and other immunotherapy
  • Plan to effectively implement evidence-based new approaches of combination regimens with checkpoint inhibitors as they become available
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Society for Immunotherapy of Cancer.

ACKNOWLEDGEMENT

This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech, and Tesaro, A GSK Company.

TUITION

Complimentary

JointlyAccreditedProvider Logo

CREDIT DESIGNATION STATEMENTS

Live Activity

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

June 10, 2020
• 12:00pm – 1:00pm ET: Refining Patient Selection for Biomarker-Directed Immunotherapy

July 24, 2020
• 12:00pm – 1:00pm ET: Optimizing Management of Adverse Events Associated with Immunotherapy
• 1:00pm – 2:00pm ET: Life After Immunotherapy: Coordinating Care and Survivorship Plans

August 26, 2020
• 11:00am – 12:00pm ET: Evidence-Based Updates on Checkpoint Inhibitors in the Metastatic Setting: Diving into Emerging Combinations

Enduring Material

The enduring material will be available from June 10, 2020 – February 28, 2021.

TARGET AUDIENCE

Medical, surgical, and radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test..

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Roy S. Herbst, MD, PhD Consulting Fees: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Midas Health Analytics, Mirati Theraputics, Nektar, Neon Theraputics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen
Contracted Research: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company
Other: Junshi Pharmaceuticals
Ignacio I. Wistuba, MD Consulting Fees: AstraZeneca/Medimmune, Asuragen, Bayer, Bristol-Myers Squibb, Guardant Health, Genentech/Roche, GlaxoSmithKline, HTG Molecular, Merck, MSD, Pfizer
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Genentech/Roche, MSD, Pfizer
Contracted Research: Adaptive, Adaptimmune, Akoya, Amgen, Bayer, Bristol-Myers Squibb, DepArray, EMD Sorono, Genentech, HTG Molecular, Iovance, Johnson & Johnson, Karus, Medimmune, Merck, Novartis, Oncocyte, Oncoplex, Pfizer, Takeda, 4D
Michael J. Overman, MD Consulting Fees: AgilVax, Takeda Pharmaceuticals (Japan), Acrotech Biopharma, Novartis Pharmaceuticals Corp, AztraZeneca
Contracted Research: Merck, BMS, AstraZeneca, Gritstone, Apexigen
Michelle Rohlfs, RN, FNP-BC, AOCNP Nothing to Disclose
Alan Nguyen, LCSW, OSW-C Nothing to Disclose
Brian I. Rini, MD Consulting Fees: Merck, BMS, Pfizer, AVEO, Alkermes
Contracted Research: Merck, BMS, Genentech, AstraZeneca

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Stone, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.